Humacyte, Inc. (HUMA): Cash & Equivalents
$50.50M
As of 2025-12-31
$79.90M
As of 2026-06-30
-30.4%
3-year compound annual growth
+4.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.50M | +12.4% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $44.94M | -44.1% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $80.45M | -46.3% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $149.77M | -31.1% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $217.50M | +444.7% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $39.93M | n/a | 2022-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $8.08M | -45.9% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $4.62M | -29.0% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.66M | -15.4% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $124.22M | -18.6% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $89.25M | +158.2% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $347.56M | +16.5% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $32.49M | -87.4% |
Compare HUMA, ALGS, OTLK, DYAI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗